4th Quarter - Report — VAN HEUVELEN STRATEGIES, LLC for ALLERGAN PLC (FORMERLY KNOWN AS ACTAVIS) (2016)

Firm

VAN HEUVELEN STRATEGIES, LLC

Client

ALLERGAN PLC (FORMERLY KNOWN AS ACTAVIS)

Income

$30,000

Expenses

—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to the CMS Part B Drugs Payment Model Demo Issues related to Zika funding Issues related to counterfeit drugs H.R. 5325 - Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2017, and Zika Response and Preparedness Act H.R. 34 - 21st Century Cures Act S. 2615 - Increasing Competition in Pharmaceuticals Act H.R. 4784 -Lower Drug Costs through Competition Act

Lobbyist	Covered position, as disclosed
ROBERT VAN HEUVELEN	Chief of Staff to Senator Kent Conrad
STEPHEN DOUGLAS WARD	Chief of Staff to Senator Jeff Bingaman

Contacted: Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 5325 (114th), H.R. 34 (114th), H.R. 4784 (114th), S. 2615 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.